Mazdutide Dosing Protocol: 10 mg Vial — Full Titration & Maintenance Guide

Mazdutide Dosing Protocol: 10 mg Vial — Full Titration & Maintenance Guide

Quickstart highlights

Mazdutide (IBI362) simultaneously activates GLP-1 receptors (insulin secretion, glucagon suppression, appetite reduction) and glucagon receptors (hepatic fat oxidation, thermogenesis, glycogenolysis).

  • Concentration: 5 mg/mL (10 mg vial + 2 mL bacteriostatic water).
  • At 5 mg/mL: 3 mg = 60 units (0.6 mL), 6 mg = 120 units (1.2 mL), 9 mg = 180 units (1.8 mL).
  • GLORY-1 Phase 3: 6 mg once weekly achieved 14.5% body weight reduction at 36 weeks.
  • Use a 3 mL syringe for the 6 mg and 9 mg doses — volumes exceed 1 mL.
  • One 10 mg vial provides ~1.67 doses at 6 mg/week; plan weekly reconstitution at this dose level.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-8300060Once weekly3 mg — 60 units; 10 mg vial provides ~3.3 doses at this level
9-166000120Once weekly6 mg maintenance — 120 units (1.2 mL); use 3 mL syringe; vial provides ~1.67 doses
17+9000180Once weekly9 mg high-dose — 180 units (1.8 mL); GLORY Phase 3 high-dose arm; approximately 1.11 doses per vial

Your free Mazdutide tracker

  • Dose reminders
  • Injection logging
  • Cycle progress
Add your listing Already have one? Sign in

Reconstitution steps

  1. Draw 2 mL bacteriostatic water; inject slowly down the vial wall.
  2. Swirl gently until fully dissolved; do not shake.
  3. Final concentration: 5 mg/mL (10 mg / 2 mL). For 6 mg dose: draw 1.2 mL; for 9 mg: draw 1.8 mL — use 3 mL syringe.
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days.

Supplies needed

8-week plan

  • 1 vial
  • 8 syringes
  • 2 mL bac water
  • 8 alcohol swabs

16-week plan

  • 4 vials
  • 16 syringes
  • 8 mL bac water
  • 16 alcohol swabs

24-week plan

  • 6 vials
  • 24 syringes
  • 12 mL bac water
  • 24 alcohol swabs
Need clinics? See vetted providers →
Advertisement

Protocol overview & cycle notes

Provide full-cycle mazdutide coverage from 3 mg initiation through 6–9 mg maintenance using the 10 mg vial, supporting weight loss and glycemic control via dual GLP-1/glucagon agonism per the GLORY Phase 3 protocol.

Cycle length: 24 weeks on.

Off-cycle: 8–12 weeks off; monitor HbA1c and body weight.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted at 5 mg/mL: refrigerate 2–8 °C; use within 28 days. For the 6 mg dose (1.2 mL) and 9 mg dose (1.8 mL), always use a 3 mL syringe.

Injection & tracking tips

  • Use a 3 mL syringe for doses above 5 mg — the 6 mg dose requires 1.2 mL, exceeding a standard 1 mL U-100 syringe.
  • Rotate injection sites weekly.
  • Hydration is important at higher doses — maintain ≥2 L water daily, especially at 9 mg where glucagon effects increase urinary output.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Record body weight weekly; GLORY-1 Phase 3 showed 14.5% weight reduction at 6 mg over 36 weeks.
  • Track fasting blood glucose and HbA1c every 8 weeks.
  • Monitor ALT/AST monthly at doses ≥6 mg; the glucagon component increases hepatic enzyme activity transiently.
Log your cycle in the calculator →

How this works & references

Mazdutide (IBI362) simultaneously activates GLP-1 receptors (insulin secretion, glucagon suppression, appetite reduction) and glucagon receptors (hepatic fat oxidation, thermogenesis, glycogenolysis). The GLORY-1 Phase 3 trial (NCT05564910) demonstrated 14.5% body weight reduction at 6 mg over 36 weeks. The 9 mg arm data are pending final Phase 3 analysis. Chinese regulatory approval for T2DM obtained 2023; US FDA submission is in progress.

Frequently asked questions

How many 10 mg vials do I need for a 16-week titration?
Approximately 4 vials: weeks 1–8 at 3 mg use ~2.4 vials (each vial yields ~3.3 doses); weeks 9–16 at 6 mg use ~4.8 vials (each vial yields ~1.67 doses). Round up to 4 vials total for the titration phase.
Can mazdutide treat fatty liver disease?
Emerging Phase 3 data from China suggest significant hepatic fat reduction. The glucagon receptor component directly stimulates hepatic β-oxidation, similar to survodutide and retatrutide. Formal MASH/NASH trials are under development.
Is 9 mg the maximum dose?
Based on GLORY Phase 3 protocols, 6 mg is the primary maintenance dose. A 9 mg high-dose arm is also being evaluated. Doses above 9 mg have not been formally studied in Phase 3.
How does mazdutide perform compared to semaglutide for T2DM?
Mazdutide was non-inferior to semaglutide 1 mg for HbA1c reduction in Chinese T2DM populations and showed superior weight loss. Direct comparison to higher semaglutide doses (2.4 mg) for obesity is not yet available.
What is the off-cycle protocol?
A structured 8–12 week off-cycle is recommended. Expect partial weight regain during the off-cycle — typically 30–50% of lost weight over 6 months. Discuss maintenance-dose cycling or dose de-escalation with your prescribing clinician.

Related protocols

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Sign In

Register

Reset Password

Please enter your username or email address, you will receive a link to create a new password via email.